These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Clinical experience with saquinavir.
    Author: Vella S.
    Journal: AIDS; 1995 Dec; 9 Suppl 2():S21-S25. PubMed ID: 8775803.
    Abstract:
    BACKGROUND: Saquinavir, a peptide-based, transition-state analogue of a characteristic HIV proteinase cleavage site, is a potent and highly specific inhibitor of HIV-1 and HIV-2 proteinases. COMBINATION THERAPY: Combination therapy with saquinavir at 600 mg and zidovudine at 200 mg, both three times a day, has been shown to provide greater and more sustained increases in CD4 cell counts and decreases in HIV-1 RNA plasma levels than treatment with either agent alone in antiretroviral-naive patients with symptomatic HIV infection. In previously antiretroviral-treated patients, triple combination therapy with saquinavir at 600 mg, zidovudine at 200 mg and zalcitabine at 0.75 mg three times a day was associated with greater immunological and virological responses than either saquinavir+zidovudine or zidovudine+zalcitabine, as demonstrated by 48 weeks of follow-up data. TOLERABILITY: Clinical experience to date has shown that saquinavir is well tolerated, even in patients with advanced disease, alone and in combination with zidovudine or zidovudine+zalcitabine. ONGOING STUDIES: Phase III studies to support these data and determine the effects of saquinavir on clinical end-points are continuing.
    [Abstract] [Full Text] [Related] [New Search]